Order results by:
| Issue | Title | |
| Vol 12, No 6 (2020) | Nonsteroidal anti-inflammatory drugs, muscle relaxants, and B-group vitamins in the treatment of lumbar ischialgia | Abstract similar documents |
| V. A. Shirokov, A. V. Potaturko, N. L. Terekhov | ||
| "... with meloxicam 1.5 ml (15 mg of its active ingredient) into the trigger points daily for 3 days, followed by one ..." | ||
| Vol 11, No 3 (2019) | Treatment of patients with acute and subacute lumbodynia and lumbar ischialgia | Abstract similar documents |
| V. A. Parfenov, A. I. Isaikin, T. I. Kuzminova, O. A. Chernenko, O. V. Milovanova, A. V. Romanova, N. D. Samkhaeva, Yu. M. Shor | ||
| "... and lumbar ischialgia; therefore they are referred to pain management departments or centers for specialized ..." | ||
| Vol 1, No 3-4 (2009) | TREATMENT FOR ACUTE NONSPECIFIC BACK PAIN IN OUTPATIENT PRACTICE | Abstract similar documents |
| O. N. Gerasimova, V. A. Parfenov | ||
| "... therapy based on meloxicam (movalis), without using physiotherapy, acupuncture and manual therapy ..." | ||
| Vol 12, No 2 (2020) | Efficacy of tolperisone versus meloxicam in the treatment of nonspecific acute neck pain | Abstract similar documents |
| K. V. Skorobogatykh, Yu. E. Azimova | ||
| "... meloxicam 15 mg/day for 14 days. Patients and methods. The observational program covered 37 patients aged ..." | ||
| Vol 3, No 3 (2011) | Use of amelotex to treat patients with acute musculoskeletal pain in the back and grade 1 essential hypertension | Abstract similar documents |
| E. V. Podchufarova, N. N. Yakhno | ||
| "... of the safety and efficacy of amelotex (meloxicam injectable dosage form) in an intramuscular dose of 15 mg/day ..." | ||
| Vol 3, No 4 (2011) | Pharmacoeconomic analysis of the use of movalis (meloxicam) in patients with nonspecific back pain | Abstract similar documents |
| O. N. Gerasimova, V. A. Parfenov | ||
| "... The paper analyzes the use of movalis (meloxicam) in 150 patients with nonspecific back pain ..." | ||
| Vol 10, No 3 (2018) | Treatment of patients with acute and subacute dorsalgia | Abstract similar documents |
| O. N. Gerasimova, V. A. Parfenov, E. Yu. Kalimeeva | ||
| "... meloxicam 15 mg/day orally or intramuscularly or first 15 mg/day intramuscularly and then orally ..." | ||
| Vol 4, No 2 (2012) | Clinical experience with meloxicam (Movalis®) in nonspecific back pain and radiculopathy | Abstract similar documents |
| O N Gerasimova, V A Parfenov | ||
| "... of the treatment in patients with acute, subacute, or chronic pain was 12.1±5.2, 17.1±5.7, and 18.0±7.9 days ..." | ||
| Vol 13, No 2 (2021) | Pain reliever combinations in treatment of patients with acute musculoskeletal back pain | Abstract similar documents |
| R. V. Gorenkov, M. N. Dadasheva, D. I. Lebedeva, I. V. Choi | ||
| "... Russian drugs meloxicam (Amelotex 15 mg per day), tolperison (Kalmirex), and a neurotropic multivitamin ..." | ||
| Vol 17, No 2 (2025) | Chronic non-specific low back pain in combination with tension-type headache, issues of therapy optimization | Abstract similar documents |
| A. A. Golovacheva, G. R. Tabeeva | ||
| "... static postures during the day) in combination with individual kinesiotherapy and optimal pharmacotherapy ..." | ||
| Vol 12, No 3 (2020) | Experience with chondroitin sulfate in the combination therapy of lower back pain | Abstract similar documents |
| O. A. Shavlovskaya, I. D. Romanov, Yu. S. Prokofyeva | ||
| "... ) from the 4th injection (on day 7). A control group (n=30) used meloxicam 7.5 mg twice daily for 7—10 ..." | ||
| Vol 14, No 1 (2022) | Kinesiotherapy and non-steroidal anti-inflammatory drugs for nonspecific lumbago | Abstract similar documents |
| A. A. Golovacheva, V. A. Golovacheva, V. A. Parfenov | ||
| "... patients' adherence to kinesiotherapy, relieving pain in the first days of treatment. A specific NSAID ..." | ||
| Vol 6, No 2 (2014) | Epidural glucocorticoid use for vertebrogenic pain | Abstract similar documents |
| M.V. Churyukanov, O.A. Chernenko | ||
| Vol 1, No 3-4 (2009) | DIAGNOSTICS AND TREATMENT OF LOW BACK PAIN | Abstract similar documents |
| R. A. Altunbaev, M. Z. Sabirova | ||
| "... , and other agents. The data of clinical trials of meloxicam used in LBP are presented. The currently ..." | ||
| Vol 7, No 3 (2015) | Treatment for low back pain, use of meloxicam | Abstract similar documents |
| E. Yu. Suslova, V. A. Parfenov | ||
| "... of NSAIDs, the high efficiency and safety of using meloxicam in different dosage forms are outlined ..." | ||
| Vol 7, No 1 (2015) | Regression of lumbar disk herniation | Abstract similar documents |
| G. Yu Evzikov, A. I. Isaikin, A. V. Kavelina, E. V. Shashkova, N. N. Alipbekov | ||
| Vol 8, No 1 (2016) | Management of patients with neck pain | Abstract similar documents |
| E. A. Chechet, V. A. Parfenov | ||
| "... are indicated in patients with chronic cervicalgia. There is evidence on the efficacy and safety of meloxicam ..." | ||
| Vol 2, No 4 (2010) | Osteoarthrosis or osteoarthritis? The name of the disease through the eyes of a practitioner | Abstract similar documents |
| N. A. Khitrov | ||
| Vol 11, No 3 (2019) | Back pain and osteoporosis | Abstract similar documents |
| A. I. Isaikin, O. Yu. Isaikina, T. I. Shadyzheva, Yu. M. Shor, M. S. Kachanovsky | ||
| "... the characteristics of pain syndrome in OP patients with nonspecific chronic vertebrogenic lumbar ischialgia (CLI ..." | ||
| Vol 14, No 5 (2022) | Emotional disorders and their therapy in chronic low back pain | Abstract similar documents |
| A. I. Isaikin, T. I. Nasonova, A. Kh. Mukhametzyanova | ||
| Vol 2, No 4 (2010) | Management of patients with back pain in outpatient practice | Abstract similar documents |
| O. N. Gerasimova, V. A. Parfenov | ||
| "... (NSAID) meloxicam (Movalis) for nonspecific back pain and radiculopathy in the outpatient practice ..." | ||
| Vol 3, No 2 (2011) | Issues of safety and pharmacoeconomics in the treatment of chronic pain in the back and limbs | Abstract similar documents |
| V. A. Parfenov, O. N. Gerasimova | ||
| "... of various NSAIDs. The use of the selective cyclooxygenase-2 inhibitor meloxicam (Movalis) is noted to cause ..." | ||
| Vol 13, No 6 (2021) | Meloxicam efficacy and safety in treatment of pain syndromes of different localization according to domestic studies | Abstract similar documents |
| O. A. Shavlovskaya, I. A. Bokova, N. I. Shavlovskiy | ||
| "... the drug is against COX-2, and the less toxic it is. Meloxicam belongs to the predominantly selective COX-2 ..." | ||
| Vol 11, No 1 (2019) | Management of patients with acute back pain now and 10 years ago | Abstract similar documents |
| V. A. Parfenov, E. Yu. Kalimeeva, О. N. Gerasimova | ||
| Vol 11, No 2 (2019) | Differential chemoreactome analysis of synergistic combinations of tolperisone and nonsteroidal anti-inflammatory drugs | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova, L. V. Stakhovskaya, V. A. Semenov, A. N. Gromov | ||
| "... (dexketoprofen, etoricoxib, meloxicam, naproxen, and diclofenac). The biological activities of the molecules ..." | ||
| Vol 11, No 4 (2019) | Chronic lower back pain: diagnosis and current principles of therapy | Abstract similar documents |
| V. A. Golovacheva, A. I. Isaikin | ||
| "... and safety of meloxicam in non-specific NSAIDs. ..." | ||
| Vol 6, No 3 (2014) | Myofascial pain: from Virchow's to our days | Abstract similar documents |
| I. V. Egorov | ||
| "... drugs and further to the increase of their doses because the treatment is ineffective. Modern-day ..." | ||
| Vol 12, No 5 (2020) | The positive and negative effects of using transdermal nonsteroidal anti-inflammatory drugs: chemoreactome analysis | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova, T. R. Grishina, V. A. Semenov | ||
| "... profiling of six NSAIDs (meloxicam, diclofenac, ibuprofen, ketoprofen, nimesulide, and dexketoprofen ..." | ||
| Vol 9, No 2 (2017) | Role of a muscle factor in the development of low back pain | Abstract similar documents |
| A. I. Isaikin, G. E. Shevtsova, D. O. Rozhkov, A. V. Kavelina, M. A. Ivanova | ||
| "... , and nonsteroidal anti-inflammatory drugs as first-line analgesic agents. Meloxicam is noted to be highly effective ..." | ||
| Vol 9, No 1 (2017) | Comparison of the efficacy of the multimodal serotonergic antidepressants trazodone and vortioxetine in the treatment of patients with endogenous depression: A meta-analysis of double-blind randomized placebo-controlled trials | Abstract similar documents |
| D. S. Danilov | ||
| "... in Group 1: a) therapy with trazodone at an average dose of about 300 mg/day significantly more frequently ..." | ||
| Vol 11, No 2S (2019): Спецвыпуск: боль в спине и конечностях | Psychological methods in the treatment of chronic nonspecific low back pain | Abstract similar documents |
| V. A. Golovacheva, A. A. Golovacheva, T. G. Fateeva | ||
| Vol 7, No 3 (2015) | Efficiency of epilepsy treatment in the Moscow Region under the present-day conditions of drug provision | Abstract similar documents |
| Irina Gennadyevna Rudakova, Yu. A. Belova | ||
| Vol 2, No 3 (2010) | Clinical experience with ceraxon used in ischemic stroke | Abstract similar documents |
| V. A. Parfenov, T. G. Fateyeva, O. V. Kosivtsova | ||
| "... cerebrovascular diseases. The efficiency and safety of Ceraxon intravenously in a dose of2000 mg/day for 10 days ..." | ||
| Vol 16, No 3 (2024) | Therapeutic outcomes in patients with acute non-specific (musculoskeletal) pain according to the FORTE (ФОРТЕ) observational study | Abstract similar documents |
| V. A. Parfenov | ||
| "... the medication Nalgesin® forte 550 mg 1–3 times a day for pain relief; the medication was discontinued when ..." | ||
| Vol 13, No 6 (2021) | Multicenter, randomized, double-blind study of the efficacy and safety of prolonged release tolperisone hydrochloride 450 mg (Mydocalm® Long, once daily) and tolperisone hydrochloride 150 mg (three times daily) for acute non-specific lower back pain | Abstract similar documents |
| V. A. Parfenov, E. I. Bogdanov, V. B. Laskov, N. S. Makarov, N. V. Pisova, E. A. Salina, Zh. Yu. Chefranova, L. V. Chichanovskaya | ||
| "... for patients, since it reduces the frequency of drug administration per day: from three immediate release ..." | ||
| Vol 16, No 5 (2024) | Gidazepam – daytime tranquilizer for the treatment of anxiety | Abstract similar documents |
| Yu. E. Azimova, D. S. Petelin | ||
| "... and procognitive effects. In the lower range of therapeutic doses (20–50 mg/day), the drug has antiasthenic ..." | ||
| Vol 3, No 3 (2011) | Poststroke cognitive impairments and their therapy with ceraxon | Abstract similar documents |
| N. V. Shakhparonova, A. S. Kadykov, E. M. Kashina | ||
| "... cognitive impairments as disorders of memory, attention, and thinking. Results and discussion. Ten-day ..." | ||
| Vol 3, No 1 (2011) | Current aspects of the epidemiology and treatment of chronic brain ischemiain the presence of essential hypertension (results of the CALIPSO program) | Abstract similar documents |
| E. I. Chukanova | ||
| "... . The patients received dropwise intravenous Cavinton as infusions within the first week (25 mg on days 1 to 4 ..." | ||
| Vol 2, No 2 (2010) | Clinical electroencephalographic criteria for the efficacy of rispolept therapy in children with Tourette's syndrome | Abstract similar documents |
| V. P. Zykov, S. A. Kabanova | ||
| "... years who took rispolept in a dose of 2-3 mg/day. The clinical and electroencephalographic assessment ..." | ||
| Vol 10, No 1 (2018) | Treatment of vertigo in elderly patients with chronic cerebrovascular disease | Abstract similar documents |
| S. N. Duma | ||
| "... who took betahistine 48 mg/day, intravenous Mexidol® 5.0 ml for 10 days, then 375 mg tablets daily ..." | ||
| Vol 12, No 2 (2020) | Investigation of the efficiency of various antidepressant replacement regimens in the development of SSRI-induced apathy syndrome | Abstract similar documents |
| V. E. Medvedev, R. A. Kardashyan, V. I. Frolova, A. M. Burno, S. V. Nekrasova, V. I. Salyntsev | ||
| "... . The patients were randomized to groups: 1) 35 patients were switched to milnacipran (Ixel 50–100 mg/day ..." | ||
| Vol 5, No 1 (2013) | Practical aspects of the use of extended-release ropinirole (requip modutab) in the treatment of Parkinson’s disease | Abstract similar documents |
| Oleg Semenovich Levin, V K Datiyeva | ||
| "... . The starting dose of the drug was 2 mg/day in all the cases. Then it was increased once weekly until ..." | ||
| Vol 16, No 4 (2024) | Aviandr is a new original drug for treating anxiety | Abstract similar documents |
| V. A. Parfenov | ||
| "... ; 75 % women) were randomized to receive Aviandr 40 mg/day (group 1; n=42) or 60 mg/day (group 2; n ..." | ||
| Vol 12, No 2 (2020) | Etoricoxib can be used for chronic nonspecific back pain: a new indication of the well-known drug | Abstract similar documents |
| A. E. Karateev | ||
| "... , controlled studies of patients with CNSBP have indicated that etoricoxib at a dose of 60 mg/day ..." | ||
| Vol 4, No 3 (2012) | Experience in correcting brain edema in cerebral infarction | Abstract similar documents |
| E V Eliseyev, T Yu Nedorostkova, Sofia Alekseyevna Rumyantseva, V V Afanasyev | ||
| "... -lysine aescinate in a daily dose of10 ml in a slow dropwise manner during the first 3 days. Results ..." | ||
| Vol 3, No 3 (2011) | Treatment for poststroke spasticity, the use of mydocalm | Abstract similar documents |
| V. A. Parfenov | ||
| "... patients. Therapeutic exercises that should be started just on the first days of stroke are noted to play ..." | ||
| Vol 15, No 6 (2023) | Choline alfoscerate in the correction of cognitive impairment | Abstract similar documents |
| O. A. Shavlovskaya, I. D. Romanov, I. A. Bokova | ||
| "... in the treatment of CI, it can be concluded that oral administration of CA at a dose of 600 mg/day can ..." | ||
| Vol 10, No 1S (2018): СПЕЦВЫПУСК: ЭПИЛЕПСИЯ | An open-label prospective clinical study of the efficacy and tolerability of brand-name and generic levetiracetam in the monotherapy of focal epilepsy in adults | Abstract similar documents |
| V. A. Karlov, P. N. Vlasov, I. A. Zhidkova | ||
| "... and gLEV were 1000 and 1500 mg/day, respectively. Results and discussion. The results of the clinical ..." | ||
| Vol 2, No 4 (2010) | Experience in using ceretone (choline alfoscerate) in brain concussion | Abstract similar documents |
| N. G. Voropay, O. B. Doronina, B. M. Doronin | ||
| "... /day for 10 days; the other 37 patients formed a control group. A one-year follow-up indicated ..." | ||
| Vol 1, No 2 (2009) | VESTIBULAR VERTIGO. EXPERIENCE IN USING BETAVER | Abstract similar documents |
| V. A. Parfenov, O. V. Abdulina | ||
| "... ). All the examinees took betaver in a dose of 48 mg/day for 30 days. Betaver treatment resulted ..." | ||
| Vol 15, No 2 (2023) | Possibilities of multimodal neuroprotection in patients with chronic cerebral ischemia on the background of arterial hypertension and atherosclerosis | Abstract similar documents |
| I. A. Gribacheva, T. F. Popova, E. V. Petrova, A. V. Zvonkova | ||
| "... by drip infusion (500 mg 1 time per day) for 14 days, followed by oral administration of the drug Mexidol ..." | ||
| Vol 13, No 3 (2021) | Oxcarbazepine as the initial monotherapy of focal epilepsy in adolescents and adults | Abstract similar documents |
| T. N. Pushkar, A. M. Azhigova, P. N. Vlasov, A. B. Kozhokaru | ||
| "... half of patients (52.9%) were prescribed 1200 mg/day of OXC, 12.3% – <1200 mg/day, and only in 6 ..." | ||
| Vol 15, No 2 (2023) | Withdrawal of valproic acid during pregnancy in women with epilepsy | Abstract similar documents |
| H. I. Navumava, P. N. Vlasov, A. I. Prusakova, A. A. Usoltseva, N. A. Shnayder, D. V. Dmitrenko | ||
| "... of 32 patients (21.8%) received VA at a dose of <700 mg/day; 10 (31.3%) – 700–1000 mg/day, 15 (46 ..." | ||
| Vol 5, No 2 (2013) | Dabigatran experience in primary and secondary prevention of cardioembolic stroke | Abstract similar documents |
| Maksim Alekseyevich Domashenko, M Yu Maksimova, D Z Korobkova, M E Gafarova | ||
| "... in 45 patients with cerebrovascular diseases are presented. Most patients received dabigatran 14 days ..." | ||
| Vol 5, No 1 (2013) | Thoracic spine pain | Abstract similar documents |
| Aleksey Ivanovich Isaikin, A V Kavelina | ||
| "... for thoracalgia includes a combination of non-drug and drug therapies. The cyclooxygenase 2 inhibitor meloxicam ..." | ||
| Vol 9, No 4 (2017) | Antitumor effects of the combined use of vitamins B1, B6, and B12 | Abstract similar documents |
| L. V. Stakhovskaya, O. A. Gromova, I. Yu. Torshin, M. V. Filimonova | ||
| "... of thiamine disulfide, pyridoxine hydrochloride, and cyanocobalamin (neurobion 110 mg/kg/day) on the growth ..." | ||
| Vol 1, No 2 (2009) | ACUTE BACK PAIN IN THE OUTPATIENT SETTING AND ITS TREATMENT WITH MYDOCALM AND MIRLOX | Abstract similar documents |
| S. V. Verbitskaya, V. A. Parfenov, K. N. Borisov | ||
| "... back pain, 30 patients were treated with mirlox (7,5- 15 mg/day) and 30 patients received mirlox ..." | ||
| Vol 2, No 2 (2010) | Cervicogenic headache: the specific features of complex therapy with Amelotex and CompligamV | Abstract similar documents |
| M. L. Pospelova | ||
| "... in a dose of 15 mg/day for 6 days and CompligamV in a dose of one ampoule for 15 days was conduced in 30 ..." | ||
| Vol 4, No 2 (2012) | Efficacy of paxil in the treatment of depressions in elderly males | Abstract similar documents |
| N A Tyuvina, S V Prokhorova, T N Maksimova | ||
| "... .3%)], and bipolar affective disorder [n = 9 (25.7%)] were examined. The efficacy of paxil 20—40 mg/day ..." | ||
| Vol 4, No 1 (2012) | Experience in using sulpiride in non-psychotic endogenous depressive-hypochondriacal disorders | Abstract similar documents |
| Nina Arkadyevna Tyuvina, V. V. Balabanova, E M Goncharova | ||
| "... in an initial dose of50—100 mg/day; the dose was, if required, increased up to 400—600 mg/day. Results. After 2 ..." | ||
| Vol 1, No 1 (2009) | ETORICOXIB: THERAPEUTIC POTENTIAL | Abstract similar documents |
| A. E. Karateev | ||
| "... to 120 mg/day), lower risk of gastrointestinal events, liver damage, and skin and respiratory reactions ..." | ||
| Vol 1, No 3-4 (2009) | RUSSIAN OBSERVATIONAL SURVEY OF THE SHORT-TERM EFFICACY AND TOLERABILITY OF SUSTAINED-RELEASE SODIUM VALPROATE (DEPAKINE CHRONOSPHERA®) AS A FIRST-LINE DRUG IN THE TREATMENT OF EPILEPSY | Abstract similar documents |
| E. D. Belousova, A. Yu. Ermakov | ||
| "... . The starting dose of Depakine Chronosphera® was 10-15 mg/day; the mean therapeutic dose was 20-30 mg/kg/day ..." | ||
| Vol 4, No 2 (2012) | The efficacy and tolerability of paroxetine (adepress), an antidepressant from a group of selective serotonin reuptake inhibitors, in psychoautonomic syndrome within anxiety-depressive disorders | Abstract similar documents |
| T G Voznesenskaya, N M Fokina | ||
| "... (paroxetine) was used in a dose of 10—20 mg/day for 8 weeks. Adverse reactions were observed in one-third ..." | ||
| Vol 14, No 1 (2022) | Treatment of spasticity in patients with the consequences of traumatic brain injury | Abstract similar documents |
| A. P. Kovalenko, I. A. Vozniuk, K. M. Naumov, V. Yu. Lobzin, S. Yu. Kirtaev | ||
| "... extremities. The follow-up assessment of spasticity and paresis was performed 24±3 days after BoNT injection ..." | ||
| Vol 3, No 3 (2011) | Neuropsychiatrie disorders in Parkinson's disease and their correction with the MAO-B inhibitor rasagiline (Azilect®) | Abstract similar documents |
| M. R. Nodel | ||
| "... rasagiline ' mg/day in addition to antiparkinsonian drugs. Following 6 and 24 weeks of therapy, its ..." | ||
| Vol 5, No 2 (2013) | Current possibilities of therapy for sleep disorders in Parkinson’s disease | Abstract similar documents |
| Marina Romanovna Nodel | ||
| "... to antiparkinsonian drugs, melatonin was given in a dose of 3 mg/day. The efficiency of the therapy was evaluated ..." | ||
| Vol 4, No 3 (2012) | Cognitive impairments in young people with opioid addiction and their correction | Abstract similar documents |
| Maria Lazarevna Chukhlovina | ||
| "... /day according to the degree of cognitive impairments for 3 months), there was a significant ..." | ||
| Vol 13, No 6 (2021) | Impact of the physical rehabilitation onset time in early recovery period of ischemic stroke (second stage of medical rehabilitation) on the level of daily activity and independence | Abstract similar documents |
| S. V. Kotov, L. H. Kodzokova, E. V. Isakova, A. S. Kotov | ||
| "... : to compare the effectiveness of the course of motor rehabilitation during the first 30–90 days and 91–180 ..." | ||
| Vol 12, No 2 (2020) | Myofascial pain syndrome in female patients with chronic nonspecific back pain: diagnosis and treatment | Abstract similar documents |
| D. O. Rozhkov, O. E. Zinovyeva, A. N. Barinov, I. M. Vikhlyantsev, G. Z. Mikhailova, N. V. Penkov, A. M. Nosovsky | ||
| "... with aceclofenac 200 mg/day in combination with tolperisone 450 mg/day and nondrug therapy (cognitive behavioral ..." | ||
| Vol 11, No 4 (2019) | Genetic risk factors for behavioral adverse reactions in epileptic patients taking levetiracetam | Abstract similar documents |
| A. A. Usoltseva, D. V. Dmitrenko, S. N. Zobova, E. N. Bochanova, N. A. Shnayder | ||
| "... of LEV in both children (696.1 and 500.0 mg/day, respectively; p=0.087) and adults (750.9 and 750.9 mg ..." | ||
| 1 - 70 of 236 Items | 1 2 3 4 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
